Skip to content
A

Alper DEMIREZEN

0000-0002-7305-8882

Publications (1)

Adoptive Cellular Immunotherapy in Glioblastoma: Mechanistic Insights, Clinical Progress, and Future Directions of CAR-T and TIL Therapies

Alper DEMIREZEN & Gizem Nur Mutlu · Asian Journal of Medical Principles and Clinical Practice · 2026

Glioblastoma remains the most common and lethal primary malignant brain tumour in adults, and outcomes have changed little despite maximal surgical resection, radiotherapy and temozolomide chemotherapy. Adoptive cellular immunotherapy, principally chimeric antigen receptor T-cell...

Open access Research Article 10.9734/ajmpcp/2026/v9i2464